Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates the immune system in some patients with metastatic non-small-cell lung cancer (NSCLC), increasing progression-free survival (PFS). Findings of the phase II randomized trial will be presented today at Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates the immune system in some patients with metastatic non-small-cell lung cancer (NSCLC), increasing progression-free survival (PFS). Findings of the phase II randomized trial will be presented today at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO) in Chicago.the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO) in Chicago.
